Oral direct factor Xa inhibitor gets FDA's OK

Thompson, Cheryl A.
August 2011
American Journal of Health-System Pharmacy;8/15/2011, Vol. 68 Issue 16, p1467
Academic Journal
The article reports that the Food and the Drug Administration (FDA) approved rivaroxaban, marketed as Xarelto by Janssen Pharmaceuticals Inc. for preventing deep vein thrombosis and subsequent pulmonary embolism in patients who have undergone knee or hip replacement surgery. It mentions that the drug is the first oral direct inhibitor of factor X. The article also discusses the recommended dosage and labeling details for the drug, and the adverse events observed.


Related Articles

  • Risk of venous thromboembolism with drospirenone-containing oral contraceptives. Brown, Dana A.; Vartan, Christine M. // American Journal of Health-System Pharmacy;6/1/2011, Vol. 68 Issue 11, p1003 

    Purpose. The risk of venous thromboembolism (VTE) with drospirenone-containing oral contraceptives (OCs) is reviewed. Summary. Increasing attention and media have raised awareness and concern about whether drospirenone-containing OCs increase the risk of VTE. Two studies found that when compared...

  • Novel Anticoagulants: New Evidence for Emerging Drugs and Their Potential Application in Major Lower Limb Surgery. Nikolaou, Vassilios S.; Harwood, Paul J.; Karadimas, Efthimios J.; Tan, Hiang Boon; Giannoudis, Peter V. // Current Vascular Pharmacology;Jan2011, Vol. 9 Issue 1, p54 

    No abstract available.

  • FDA actions.  // Primary Care Reports;Sep2011 Supplement, p2 

    The article reports on the approval given by the U.S. Food and Drug Administration to the oral factor Xa inhibitor rivaroxaban. The drug is designed for patients undergoing knee or hip replacement to reduce the risk of deep venous thrombosis, blood clots, and pulmonary embolism. The article...

  • New oral anticoagulant drugs -- mechanisms of action. Brighton, Timothy // Australian Prescriber;Apr2010, Vol. 33 Issue 2, p38 

    In 2008, two new oral anticoagulant drugs were registered in Australia for the prevention of venous thrombosis after elective knee or hip replacement. Rivaroxaban is a direct reversible competitive antagonist of activated factor X. Dabigatran etexilate is a direct reversible competitive...

  • New oral anticoagulants -- clinical applications. Gallus, Alex // Australian Prescriber;Apr2010, Vol. 33 Issue 2, p42 

    Rivaroxaban and dabigatran etexilate are oral anticoagulants that promise to be as effective as warfarin, but easier to use. The new drugs have shown similar or greater efficacy than low molecular weight heparins and comparable safety in the prevention of venous thromboembolism after hip or knee...

  • New Anticoagulants for the Prevention of Thromboembolism. Lepic, Kylie; Crowther, Mark // Current Pharmaceutical Design;10/21/2010, Vol. 16 Issue 31, p3472 

    No abstract available.

  • Italian population-based study shows 'high' rate of VTE after hip, knee replacement. Brockenbrough, Gina; Owens, Colleen // Orthopaedics Today Europe;May/Jun2011, Vol. 14 Issue 3, p16 

    The article focuses on a research study which shows high rate of venous thromboembolism (VTE) within 3 months of hip and knee replacement among patients in Italy.

  • Efficacy and Safety of Enoxaparin To Prevent Deep Venous Thrombosis after Hip Replacement Surgery. Spiro, Theodore E.; Johnson, Gerhard J.; Christie, Michael J.; Lyons, Roger M.; MacFarlane, Donald E.; Blasier, Ralph B.; Tremaine, M. David // Annals of Internal Medicine;7/15/94, Vol. 121 Issue 2, p81 

    Objective: To determine the most effective and safe dose of enoxaparin to prevent deep venous thrombosis in high-risk surgical patients. Design: A double-blind, randomized, multicenter clinical trial. Setting: Private, university, and government hospitals in the United States. Patients: 572...

  • Okay of rivaroxaban recommended.  // Cardiovascular Devices & Drugs;Aug2008, Vol. 14 Issue 8, p11 

    The article reports on the recommended approval of Bayer HealthCare's anticoagulant rivaroxaban by the European Committee for Medicinal Products for Human Use (CHMP). The drug is recommended for the prevention of venous blood clots in patients undergoing elective hip or knee replacement surgery....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics